Opinion

Video

Insights Into Ongoing Investigational Studies in Lung LCNEC

Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).

Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
2 expert is featured in this series.
2 expert is featured in this series.
2 experts are featured in this series.
Related Content